Anixa Biosciences (NASDAQ:ANIX) Earns Buy Rating from D. Boral Capital

Anixa Biosciences (NASDAQ:ANIX)‘s stock had its “buy” rating restated by investment analysts at D. Boral Capital in a report released on Wednesday,Benzinga reports. They presently have a $10.00 target price on the stock. D. Boral Capital’s price objective indicates a potential upside of 242.47% from the company’s previous close.

Separately, HC Wainwright restated a “buy” rating and issued a $7.00 price objective on shares of Anixa Biosciences in a report on Tuesday, November 19th.

Anixa Biosciences Price Performance

Shares of NASDAQ ANIX opened at $2.92 on Wednesday. The stock has a market capitalization of $94.02 million, a P/E ratio of -7.49 and a beta of 0.90. The firm’s 50 day simple moving average is $2.76 and its two-hundred day simple moving average is $3.03. Anixa Biosciences has a one year low of $2.07 and a one year high of $4.94.

Anixa Biosciences (NASDAQ:ANIX) last issued its earnings results on Friday, January 10th. The company reported ($0.09) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.11) by $0.02. As a group, equities analysts expect that Anixa Biosciences will post -0.46 earnings per share for the current fiscal year.

Insider Activity

In other Anixa Biosciences news, CEO Amit Kumar bought 43,000 shares of Anixa Biosciences stock in a transaction on Wednesday, January 15th. The stock was acquired at an average price of $2.23 per share, with a total value of $95,890.00. Following the acquisition, the chief executive officer now owns 559,925 shares in the company, valued at approximately $1,248,632.75. This trade represents a 8.32 % increase in their ownership of the stock. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, Director Lewis H. Titterton, Jr. acquired 10,000 shares of the company’s stock in a transaction that occurred on Friday, January 17th. The shares were acquired at an average cost of $2.57 per share, for a total transaction of $25,700.00. Following the completion of the transaction, the director now directly owns 922,334 shares of the company’s stock, valued at $2,370,398.38. The trade was a 1.10 % increase in their ownership of the stock. The disclosure for this purchase can be found here. Over the last ninety days, insiders acquired 68,289 shares of company stock worth $157,101. Insiders own 22.60% of the company’s stock.

Hedge Funds Weigh In On Anixa Biosciences

Several hedge funds and other institutional investors have recently bought and sold shares of ANIX. International Assets Investment Management LLC boosted its holdings in Anixa Biosciences by 170.0% in the third quarter. International Assets Investment Management LLC now owns 37,800 shares of the company’s stock worth $1,190,000 after purchasing an additional 23,800 shares during the last quarter. Virtu Financial LLC purchased a new stake in Anixa Biosciences during the third quarter valued at $34,000. Westside Investment Management Inc. boosted its position in Anixa Biosciences by 151.8% in the third quarter. Westside Investment Management Inc. now owns 35,000 shares of the company’s stock worth $110,000 after purchasing an additional 21,100 shares during the last quarter. Finally, Tyler Stone Wealth Management increased its position in shares of Anixa Biosciences by 100.0% during the 3rd quarter. Tyler Stone Wealth Management now owns 42,016 shares of the company’s stock valued at $132,000 after purchasing an additional 21,008 shares during the last quarter. Institutional investors own 29.13% of the company’s stock.

Anixa Biosciences Company Profile

Anixa Biosciences, Inc, a biotechnology company, develops therapies and vaccines focusing on critical unmet needs in oncology and infectious diseases. The company's therapeutics programs include the development of a chimeric endocrine receptor T-cell therapy, a novel form of chimeric antigen receptor T-cell (CAR-T) technology focusing on the treatment of ovarian cancer.